32. Đánh giá kết quả hóa trị tân hỗ trợ trong ung thư vú theo phân nhóm luminal A + luminal B-her 2 âm tính giai đoạn II-III bằng phác đồ TAC

Abstract

Luminal Breast cancer account for 60-70% breast cancer and good prognosis compare to other molecular subtypes of breast cancer. Neoadjuvant chemotherapy for Luminal breast cancer aim to be downstaging and increase survival if the patient achive pathological complete response. Objectives: The aim of this study was evaluation of results and related factors of neoadjuvant TAC- chemotherapy for Luminal A and Luminal B-HER 2 negative at Can Tho oncology hospital. Patients and methods: Single-arm trial of 54 stage II-III Luminal A and Luminal B-HER 2 negative breast cancer were treated with neoadjuvant TAC-chemotherapy regimen at Can Tho oncology hospital and Can Thơ university of medicine and pharmacy hospital from 2024 - 2025. Results: The mean age was 51.57 ± 9.6, there are 71.4% of patients with T4b, patients with N3 was 18.5%, 93.6% of patients had invasive ductal carcinoma, not otherwise specified, 92.6% were grade 2, Luminal A and Luminal B-HER 2 negative accounted for 12.8% and 81.8% respectively. The overall clinical response rate was 87%. Of which, partial clinical response was about 70.3%, complete clinical response was about 16.7%. Complete response to treatment on the tumor was 13%, on the axillary lympho node was 18.5%, on both the room and the tumor was 9,3%. Neoadjuvant chemotherapy toxicity mainly included 14.8%, neutropenia, 16.7% perinneural pathy, 3% diarrhea and 3.7% elevation of liver transaminases. Conclusion: Neoadjvant chemotherapy with TAC regimen for satge II-III breast cancer is quite effective and aceptable